-
Pfizer/GSK-Backed ViiV Healthcare's HIV Drug Associated With Increased Resistance, WHO Report Says
Tuesday, March 5, 2024 - 1:57pm | 454The World Health Organization (WHO) released its latest HIV Drug Resistance (HIVDR) Report, shedding light on the growing areas of drug resistance and providing crucial recommendations for countries to navigate potential challenges. The report carried both optimistic and concerning...
-
Pfizer, GSK-Backed ViiV First To Get FDA Approval For HIV Shots: What You Need To Know
Friday, January 22, 2021 - 1:19am | 536In a first, a monthly injectable HIV drug made by a GlaxoSmithKline plc (NYSE: GSK)- and Pfizer Inc (NYSE: PFE)-owned company has received the approval of the United States Food and Drug Administration. What Happened: The injectable — Cabenuva — is designed to replace the current...
-
Mylan Price Target Slashed Even As TLD Drug Receives Tentative Approval
Monday, August 7, 2017 - 11:56am | 505Morgan Stanley reduced its price target on the shares of Mylan N.V. (NASDAQ: MYL) following downward revision to its estimates due to the IMS trends, generic price pressure and uncertain new launch timing. Meanwhile, in a separate note, Mylan announced its NDA for TLD, a combo of Lamivudhine...
-
Advances In HIV, Hep C Treatments Could Spark Renewed Interest In Biotech Stocks
Wednesday, June 18, 2014 - 9:38am | 768This month marks 33 years since the U.S. Centers for Disease Control and Prevention (CDC) reported on a rare lung infection affecting a group of gay men – one of the first known medical mentions of what later became known as the AIDS outbreak. The World Health Organization says that, over...